Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Vor Bio price target lowered to $15 from $30 at JMP Securities » 09:06
05/13/22
05/13
09:06
05/13/22
09:06
VOR

Vor Bio

$4.42 /

+0.015 (+0.34%)

JMP Securities analyst…

JMP Securities analyst Silvan Tuerkcan lowered the firm's price target on Vor Bio to $15 from $30 to reflect higher discounts on future cash flows of growth companies pre-revenue but keeps an Outperform rating on the shares after its Q1 results. The company's quarter-end cash balance of $182M should support operations into Q4 of 2023, with Vor Bio remaining on track to deliver a key first-in-human dataset in the second half of the year to validate its approach in AML, the analyst tells investors in a research note.

ShowHide Related Items >><<
VOR Vor Bio
$4.42 /

+0.015 (+0.34%)

VOR Vor Bio
$4.42 /

+0.015 (+0.34%)

04/27/22 Goldman Sachs
Vor Bio initiated with a Neutral at Goldman Sachs
03/21/22 Barclays
Vor Biopharma price target lowered to $26 from $56 at Barclays
03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
VOR Vor Bio
$4.42 /

+0.015 (+0.34%)

VOR Vor Bio
$4.42 /

+0.015 (+0.34%)

Earnings
Vor Bio reports Q1 EPS (61c), consensus (51c) » 17:09
05/12/22
05/12
17:09
05/12/22
17:09
VOR

Vor Bio

$4.42 /

+0.015 (+0.34%)

Cash, cash equivalents…

Cash, cash equivalents and investments were $181.6 million as of March 31, 2022, which is anticipated to fund operations into the fourth quarter of 2023. "We remain fully focused on generating first-in-human clinical data from VBP101, our Phase 1/2a clinical trial of VOR33 in patients with relapsed/refractory AML, which will provide important proof of concept for our proprietary platform and has the potential to transform outcomes for patients with blood cancers," said Dr. Robert Ang, Vor Bio's President and Chief Executive Officer. "We also continue to make progress on our allogeneic healthy donor-derived CAR-T therapy VCAR33ALLO, which remains on track for IND submission in 1H 2023, and look forward to the opening of our new in-house eHSC and CAR-T clinical manufacturing facility later this year."

ShowHide Related Items >><<
VOR Vor Bio
$4.42 /

+0.015 (+0.34%)

VOR Vor Bio
$4.42 /

+0.015 (+0.34%)

04/27/22 Goldman Sachs
Vor Bio initiated with a Neutral at Goldman Sachs
03/21/22 Barclays
Vor Biopharma price target lowered to $26 from $56 at Barclays
03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
VOR Vor Bio
$4.42 /

+0.015 (+0.34%)

VOR Vor Bio
$4.42 /

+0.015 (+0.34%)

Initiation
Vor Bio initiated with a Neutral at Goldman Sachs » 04:50
04/27/22
04/27
04:50
04/27/22
04:50
VOR

Vor Bio

$5.61 /

+0.05 (+0.90%)

Goldman Sachs analyst…

Goldman Sachs analyst Andrea Tan initiated coverage of Vor Bio with a Neutral rating and $6 price target. Vor is an early stage clinical company leveraging novel cell and gene engineering techniques to cure blood cancers, Tan tells investors in a research note. The analyst awaits proof-of-concept clinical data for VBP101 in patients with acute myeloid leukemia in the second half of 2022. Tan is on the sidelines given the inherent technology risk and notes VOR33's value proposition of improved safety from CD33-targeted therapies and enhanced clinical benefit "remains to be determined."

ShowHide Related Items >><<
VOR Vor Bio
$5.61 /

+0.05 (+0.90%)

VOR Vor Bio
$5.61 /

+0.05 (+0.90%)

03/21/22 Barclays
Vor Biopharma price target lowered to $26 from $56 at Barclays
03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$5.61 /

+0.05 (+0.90%)

VOR Vor Bio
$5.61 /

+0.05 (+0.90%)

Hot Stocks
Vor Bio to present two abstracts at Keystone Symposia Precision meeting » 08:16
04/25/22
04/25
08:16
04/25/22
08:16
VOR

Vor Bio

$5.63 /

-0.395 (-6.56%)

Vor Bio announced that…

Vor Bio announced that two abstracts have been accepted for poster presentations at the Keystone Symposia Precision Genome Engineering meeting, held April 27 to May 1 in Keystone, Colorado. The presentations include two posters and a workshop discussion featuring data on multiplex gene editing in human hematopoietic stem cells using various genome editing technologies. The data demonstrate how Vor Bio's novel platform, which genetically modifies healthy donor hematopoietic stem cells to remove select cell surface targets, enables targeted therapies to selectively destroy cancer cells while sparing the healthy cells. "As most tumor antigens are also expressed on normal blood cells, traditional multi-targeted immunotherapy increases the risk of severe cytopenia," explained Tirtha Chakraborty, Ph.D., Vor Bio's Chief Scientific Officer. "We are excited to present how we can potentially address this challenge with a safer approach, with minimum translocation risk, using our platform that removes two or more target antigens from the donor HSCs. This approach to transplant, coupled with targeted therapies, may enable the delivery of more efficacious and durable treatments."

ShowHide Related Items >><<
VOR Vor Bio
$5.63 /

-0.395 (-6.56%)

VOR Vor Bio
$5.63 /

-0.395 (-6.56%)

03/21/22 Barclays
Vor Biopharma price target lowered to $26 from $56 at Barclays
03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$5.63 /

-0.395 (-6.56%)

VOR Vor Bio
$5.63 /

-0.395 (-6.56%)

Over a month ago
Hot Stocks
Vor Bio says Slapak to retire as Chief Medical Officer as of May 6 » 16:07
04/14/22
04/14
16:07
04/14/22
16:07
VOR

Vor Bio

$5.85 /

+0.52 (+9.76%)

In a regulatory filing,…

In a regulatory filing, Vor Biopharma stated that on April 11, the company and Christopher Slapak, M.D., Chief Medical Officer of the company, agreed that Dr. Slapak's employment with the company will terminate effective May 6, in connection with Dr. Slapak's retirement from the company.

ShowHide Related Items >><<
VOR Vor Bio
$5.85 /

+0.52 (+9.76%)

VOR Vor Bio
$5.85 /

+0.52 (+9.76%)

03/21/22 Barclays
Vor Biopharma price target lowered to $26 from $56 at Barclays
03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$5.85 /

+0.52 (+9.76%)

VOR Vor Bio
$5.85 /

+0.52 (+9.76%)

Conference/Events
Vor Bio participates in a conference call hosted by JMP Securities » 04:55
04/04/22
04/04
04:55
04/04/22
04:55
VOR

Vor Bio

$6.35 /

+0.38 (+6.37%)

JMP Securities holds a…

JMP Securities holds a conference call with management on April 4 hosted by JMP Securities.

ShowHide Related Items >><<
VOR Vor Bio
$6.35 /

+0.38 (+6.37%)

VOR Vor Bio
$6.35 /

+0.38 (+6.37%)

03/21/22 Barclays
Vor Biopharma price target lowered to $26 from $56 at Barclays
03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$6.35 /

+0.38 (+6.37%)

VOR Vor Bio
$6.35 /

+0.38 (+6.37%)

Conference/Events
Vor Bio participates in a conference call hosted by JMP Securities » 06:24
03/31/22
03/31
06:24
03/31/22
06:24
VOR

Vor Bio

$6.22 /

-0.19 (-2.96%)

JMP Securities holds a…

JMP Securities holds a conference call with management on April 4 hosted by JMP Securities.

ShowHide Related Items >><<
VOR Vor Bio
$6.22 /

-0.19 (-2.96%)

VOR Vor Bio
$6.22 /

-0.19 (-2.96%)

03/21/22 Barclays
Vor Biopharma price target lowered to $26 from $56 at Barclays
03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$6.22 /

-0.19 (-2.96%)

VOR Vor Bio
$6.22 /

-0.19 (-2.96%)

Hot Stocks
Vor Bio, Akron BioProducts to develop cGMP nucleases » 10:12
03/22/22
03/22
10:12
03/22/22
10:12
VOR

Vor Bio

$7.64 /

+0.06 (+0.79%)

Akron BioProducts and Vor…

Akron BioProducts and Vor Bio announced an agreement to develop and manufacture cGMP nucleases. "This collaboration strengthens Akron's portfolio of off-the-shelf gene editing technologies while broadening Vor Bio's collection of nucleases to engineer gene modified cell therapies. Vor Bio continues to strategically invest in its proprietary manufacturing capabilities for its engineered HSC and CAR-T programs. The companies will collaborate in the development and manufacture of starting materials needed to advance potentially transformative treatments for blood cancers into the clinic," the press release reads.

ShowHide Related Items >><<
VOR Vor Bio
$7.64 /

+0.06 (+0.79%)

VOR Vor Bio
$7.64 /

+0.06 (+0.79%)

03/21/22 Barclays
Vor Biopharma price target lowered to $26 from $56 at Barclays
03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$7.64 /

+0.06 (+0.79%)

VOR Vor Bio
$7.64 /

+0.06 (+0.79%)

Recommendations
Vor Biopharma price target lowered to $26 from $56 at Barclays » 05:53
03/21/22
03/21
05:53
03/21/22
05:53
VOR

Vor Bio

$8.47 /

+0.05 (+0.59%)

Barclays analyst Carter…

Barclays analyst Carter Gould lowered the firm's price target on Vor Biopharma to $26 from $56 and keeps an Overweight rating on the shares. The company recently announced the initial engraftment data read-out from the Phase 1/2 study of VOR33 in acute myeloid leukemia was pushed to the second half of 2022, Gould tells investors in a research note. The delay, coupled with lack of clarity on enrollment, along with a challenging market environment for early-stage companies, "raises uncertainty on the timelines moving forward," says the analyst. As such, Gould pushed his projected launch data to 2026.

ShowHide Related Items >><<
VOR Vor Bio
$8.47 /

+0.05 (+0.59%)

VOR Vor Bio
$8.47 /

+0.05 (+0.59%)

03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
12/03/21 Baird
Baird start Vor Biopharma with an Outperform ahead of AML data
VOR Vor Bio
$8.47 /

+0.05 (+0.59%)

VOR Vor Bio
$8.47 /

+0.05 (+0.59%)

Conference/Events
Barclays to hold a conference » 04:55
03/17/22
03/17
04:55
03/17/22
04:55
AVTR

Avantor

$34.90 /

+0.42 (+1.22%)

, PAHC

Phibro Animal Health

$19.85 /

-0.17 (-0.85%)

, CVS

CVS Health

$107.14 /

+0.12 (+0.11%)

, ALNY

Alnylam

$158.89 /

+5.92 (+3.87%)

, LNTH

Lantheus

$54.99 /

+2.38 (+4.52%)

, BEAM

Beam Therapeutics

$59.83 /

+4.67 (+8.47%)

, HUM

Humana

$442.83 /

+2.9 (+0.66%)

, CNC

Centene

$86.83 /

+1.27 (+1.48%)

, LLY

Eli Lilly

$276.42 /

+0.87 (+0.32%)

, PINC

Premier

$35.67 /

+ (+0.00%)

, AZTA

Azenta

$84.77 /

+7.52 (+9.73%)

, EXEL

Exelixis

$20.65 /

+0.36 (+1.77%)

, THC

Tenet Healthcare

$87.65 /

+0.22 (+0.25%)

, PFE

Pfizer

$52.93 /

+0.69 (+1.32%)

, TCRX

TScan Therapeutics

$3.55 /

-0.105 (-2.87%)

, VACC

Vaccitech

$5.85 /

+0.59 (+11.22%)

, VOR

Vor Bio

$7.85 /

+0.17 (+2.21%)

, SGMO

Sangamo

$5.54 /

+0.3 (+5.73%)

, SGTX

Sigilon Therapeutics

$1.42 /

+0.09 (+6.77%)

, PIII

P3 Health Partners

$6.85 /

+0.09 (+1.33%)

, JANX

Janux Therapeutics

$17.22 /

+0.19 (+1.12%)

, KPTI

Karyopharm

$6.67 /

+0.45 (+7.23%)

, EOLS

Evolus

$10.55 /

+0.61 (+6.14%)

, EPZM

Epizyme

$1.31 /

+0.11 (+9.21%)

, BKD

Brookdale Senior Living

$6.79 /

-0.155 (-2.23%)

, MTEM

Molecular Templates

$2.50 /

+0.175 (+7.53%)

, LOGC

LogicBio Therapeutics

/

+

Global Healthcare…

Global Healthcare Conference to be held in Miami, FL on March 15-17.

ShowHide Related Items >><<
VOR Vor Bio
$7.85 /

+0.17 (+2.21%)

VACC Vaccitech
$5.85 /

+0.59 (+11.22%)

THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

TCRX TScan Therapeutics
$3.55 /

-0.105 (-2.87%)

SGTX Sigilon Therapeutics
$1.42 /

+0.09 (+6.77%)

SGMO Sangamo
$5.54 /

+0.3 (+5.73%)

PINC Premier
$35.67 /

+ (+0.00%)

PIII P3 Health Partners
$6.85 /

+0.09 (+1.33%)

PFE Pfizer
$52.93 /

+0.69 (+1.32%)

PAHC Phibro Animal Health
$19.85 /

-0.17 (-0.85%)

MTEM Molecular Templates
$2.50 /

+0.175 (+7.53%)

LOGC LogicBio Therapeutics
/

+

LNTH Lantheus
$54.99 /

+2.38 (+4.52%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

JANX Janux Therapeutics
$17.22 /

+0.19 (+1.12%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

EXEL Exelixis
$20.65 /

+0.36 (+1.77%)

EPZM Epizyme
$1.31 /

+0.11 (+9.21%)

EOLS Evolus
$10.55 /

+0.61 (+6.14%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

BKD Brookdale Senior Living
$6.79 /

-0.155 (-2.23%)

BEAM Beam Therapeutics
$59.83 /

+4.67 (+8.47%)

AZTA Azenta
$84.77 /

+7.52 (+9.73%)

AVTR Avantor
$34.90 /

+0.42 (+1.22%)

ALNY Alnylam
$158.89 /

+5.92 (+3.87%)

AVTR Avantor
$34.90 /

+0.42 (+1.22%)

02/07/22 Raymond James
Avantor price target lowered to $43 from $47 at Raymond James
02/07/22 Baird
Avantor price target lowered to $43 from $44 at Baird
02/07/22 Barclays
Avantor price target raised to $44 from $41 at Barclays
01/27/22 Barclays
Avantor price target lowered to $41 from $48 at Barclays
PAHC Phibro Animal Health
$19.85 /

-0.17 (-0.85%)

01/10/22 Barclays
Phibro Animal Health upgraded to Equal Weight from Underweight at Barclays
11/18/21 Morgan Stanley
Phibro Animal Health initiated with an Equal Weight at Morgan Stanley
08/04/21 Credit Suisse
Phibro Animal Health assumed with a Neutral at Credit Suisse
07/07/21
Fly Intel: Top five analyst downgrades
CVS CVS Health
$107.14 /

+0.12 (+0.11%)

03/09/22 UBS
Signify Health upgraded to Buy from Neutral at UBS
02/17/22 Deutsche Bank
CVS Health price target raised to $110 from $107 at Deutsche Bank
02/11/22 Raymond James
CVS Health downgraded to Outperform from Strong Buy at Raymond James
02/11/22 Raymond James
CVS Health downgraded to Outperform from Strong Buy at Raymond James
ALNY Alnylam
$158.89 /

+5.92 (+3.87%)

02/28/22 Citi
Alnylam initiated with a Buy at Citi
02/10/22 Piper Sandler
Piper Sandler 'confident' in approval of Alnylam's vutrisiran by PDUFA date
02/03/22 Guggenheim
Alnylam upgraded to Buy from Neutral at Guggenheim
01/20/22 H.C. Wainwright
Alnylam price target raised to $350 from $250 at H.C. Wainwright
LNTH Lantheus
$54.99 /

+2.38 (+4.52%)

BEAM Beam Therapeutics
$59.83 /

+4.67 (+8.47%)

01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
HUM Humana
$442.83 /

+2.9 (+0.66%)

02/03/22 Deutsche Bank
Humana price target raised to $435 from $418 at Deutsche Bank
01/11/22 Bernstein
Humana price target lowered to $431 from $470 at Bernstein
01/07/22 Truist
Humana price target lowered to $445 from $520 at Truist
01/07/22 BMO Capital
Humana price target lowered to $415 from $490 at BMO Capital
CNC Centene
$86.83 /

+1.27 (+1.48%)

02/09/22 Deutsche Bank
Centene price target raised to $88 from $84 at Deutsche Bank
02/09/22 BMO Capital
Centene price target raised to $105 from $100 at BMO Capital
02/09/22 Mizuho
Centene price target raised to $84 from $78 at Mizuho
02/04/22 Wells Fargo
Anthem, Centene have 'significant' exposure to CA Medicaid, says Wells Fargo
LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

03/10/22 Daiwa
Eli Lilly initiated with an Outperform at Daiwa
03/02/22 Goldman Sachs
Quanterix upgraded to Neutral from Sell at Goldman Sachs
02/14/22 JMP Securities
ProQR Therapeutics price target lowered to $8 from $29 at JMP Securities
02/11/22 Benchmark
AbCellera royalties could be 'substantial' from Lilly antibody, says Benchmark
PINC Premier
$35.67 /

+ (+0.00%)

11/18/21 Barclays
Premier price target raised to $36 from $34 at Barclays
11/03/21 Piper Sandler
Premier price target raised to $39 from $31 at Piper Sandler
05/28/21
Fly Intel: Top five analyst downgrades
05/28/21 Barclays
Barclays double downgrades Premier with multiple expansion less likely
AZTA Azenta
$84.77 /

+7.52 (+9.73%)

02/09/22 Needham
Azenta price target lowered to $115 from $155 at Needham
11/17/21 Stifel
Brooks Automation price target raised to $149 from $134 at Stifel
11/17/21 Stephens
Brooks Automation price target raised to $137 from $130 at Stephens
EXEL Exelixis
$20.65 /

+0.36 (+1.77%)

03/14/22 Piper Sandler
Exelixis price target lowered to $30 from $34 at Piper Sandler
02/25/22 Jefferies
Court denied MSN motion to add patents to fight with Exelixis, says Jefferies
02/18/22 H.C. Wainwright
Exelixis price target lowered to $42 from $52 at H.C. Wainwright
02/18/22 Piper Sandler
Exelixis positioned for 'strong' 2022, says Piper Sandler
THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

03/07/22 Jefferies
Tenet Healthcare price target raised to $125 from $120 at Jefferies
03/03/22 Mizuho
Tenet Healthcare price target raised to $103 from $90 at Mizuho
03/01/22 Goldman Sachs
Tenet Healthcare reinstated with a Buy at Goldman Sachs
02/10/22 UBS
UBS upgrades Tenet on 'too attractive to ignore' cash flow
PFE Pfizer
$52.93 /

+0.69 (+1.32%)

02/15/22
FDA Vaccines and Related Biological Products Advisory Committee to hold meeting
02/10/22 Mizuho
Pfizer price target lowered to $55 from $56 at Mizuho
02/09/22 Benchmark
Pfizer's Paxlovid forecast 'bodes well' for Codexis, says Benchmark
TCRX TScan Therapeutics
$3.55 /

-0.105 (-2.87%)

12/16/21 H.C. Wainwright
TScan Therapeutics initiated with a Buy at H.C. Wainwright
08/13/21 Cowen
Cowen sees upside for TScan Therapeutics, starts with Outperform
08/13/21 Cowen
TScan Therapeutics initiated with an Outperform at Cowen
08/10/21 Jefferies
TScan Therapeutics initiated with a Buy at Jefferies
VACC Vaccitech
$5.85 /

+0.59 (+11.22%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$7.85 /

+0.17 (+2.21%)

03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
12/03/21 Baird
Baird start Vor Biopharma with an Outperform ahead of AML data
SGMO Sangamo
$5.54 /

+0.3 (+5.73%)

01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
05/03/21 RBC Capital
Sangamo initiated with an Outperform at RBC Capital
SGTX Sigilon Therapeutics
$1.42 /

+0.09 (+6.77%)

12/23/21 Canaccord
Sigilon Therapeutics price target lowered to $7 from $12 at Canaccord
12/01/21 Barclays
Sigilon Therapeutics price target lowered to $7 from $16 at Barclays
11/30/21 Jefferies
Sigilon downgraded to Hold at Jefferies after 'unexpected' fibrosis finding
11/30/21 Canaccord
Sigilon Therapeutics price target lowered to $12 from $23 at Canaccord
PIII P3 Health Partners
$6.85 /

+0.09 (+1.33%)

01/04/22 William Blair
P3 Health Partners initiated with an Outperform at William Blair
12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
JANX Janux Therapeutics
$17.22 /

+0.19 (+1.12%)

07/06/21 Cowen
Cowen starts Janux with Outperform on potential of PSMA-TRACTr
07/06/21 BofA
Janux Therapeutics initiated with a Buy at BofA
07/06/21 Cowen
Janux Therapeutics initiated with an Outperform at Cowen
07/06/21 Evercore ISI
Evercore starts Janux Therapeutics at Outperform with $35 price target
KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

02/09/22 JPMorgan
Karyopharm upgraded to Neutral from Underweight at JPMorgan
11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
EOLS Evolus
$10.55 /

+0.61 (+6.14%)

01/26/22 Stifel
Evolus preannouncement shows continued execution success, says Stifel
01/20/22 Truist
Evolus upgraded to Buy from Hold at Truist
11/03/21 H.C. Wainwright
Evolus price target lowered to $15 from $22 at H.C. Wainwright
09/22/21 Stifel
Evolus positioned for aesthetics share increases through 2021, says Stifel
EPZM Epizyme
$1.31 /

+0.11 (+9.21%)

03/02/22 H.C. Wainwright
Epizyme price target lowered to $10 from $15 at H.C. Wainwright
09/09/21 Truist
MEI Pharma price target lowered to $8 from $12 at Truist
08/10/21 H.C. Wainwright
Epizyme price target lowered to $15 from $36 at H.C. Wainwright
08/09/21 Morgan Stanley
Epizyme downgraded to Underweight at Morgan Stanley on Tazverik challenges
BKD Brookdale Senior Living
$6.79 /

-0.155 (-2.23%)

06/22/21 Stifel
Brookdale Senior Living resumed with a Buy at Stifel
06/11/21 Barclays
Brookdale Senior Living upgraded to Overweight from Equal Weight at Barclays
06/07/21 Jefferies
Approval of Biogen Alzheimer's drug could be catalyst for RadNet, says Jefferies
MTEM Molecular Templates
$2.50 /

+0.175 (+7.53%)

04/21/21 BofA
Molecular Templates initiated with a Buy at BofA
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21 Jefferies
Jefferies views Molecular Templates selloff as overdone, boosts price target
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
LOGC LogicBio Therapeutics
/

+

02/03/22 William Blair
LogicBio downgraded to Market Perform on 'unfortunate setback' at William Blair
02/02/22 William Blair
LogicBio downgraded to Market Perform from Outperform at William Blair
11/17/21 Barclays
LogicBio Therapeutics price target lowered to $8 from $24 at Barclays
06/07/21
Fly Intel: Top five analyst initiations
VOR Vor Bio
$7.85 /

+0.17 (+2.21%)

VACC Vaccitech
$5.85 /

+0.59 (+11.22%)

THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

TCRX TScan Therapeutics
$3.55 /

-0.105 (-2.87%)

SGTX Sigilon Therapeutics
$1.42 /

+0.09 (+6.77%)

SGMO Sangamo
$5.54 /

+0.3 (+5.73%)

PINC Premier
$35.67 /

+ (+0.00%)

PIII P3 Health Partners
$6.85 /

+0.09 (+1.33%)

PFE Pfizer
$52.93 /

+0.69 (+1.32%)

PAHC Phibro Animal Health
$19.85 /

-0.17 (-0.85%)

MTEM Molecular Templates
$2.50 /

+0.175 (+7.53%)

LOGC LogicBio Therapeutics
/

+

LNTH Lantheus
$54.99 /

+2.38 (+4.52%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

EXEL Exelixis
$20.65 /

+0.36 (+1.77%)

EPZM Epizyme
$1.31 /

+0.11 (+9.21%)

EOLS Evolus
$10.55 /

+0.61 (+6.14%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

BKD Brookdale Senior Living
$6.79 /

-0.155 (-2.23%)

BEAM Beam Therapeutics
$59.83 /

+4.67 (+8.47%)

AZTA Azenta
$84.77 /

+7.52 (+9.73%)

AVTR Avantor
$34.90 /

+0.42 (+1.22%)

ALNY Alnylam
$158.89 /

+5.92 (+3.87%)

  • 27
    Jan
  • 14
    Sep
  • 03
    Sep
  • 16
    Jul
  • 11
    Jun
  • 30
    Apr
  • 22
    Apr
PFE Pfizer
$52.93 /

+0.69 (+1.32%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

SGTX Sigilon Therapeutics
$1.42 /

+0.09 (+6.77%)

SGMO Sangamo
$5.54 /

+0.3 (+5.73%)

PFE Pfizer
$52.93 /

+0.69 (+1.32%)

LNTH Lantheus
$54.99 /

+2.38 (+4.52%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

EXEL Exelixis
$20.65 /

+0.36 (+1.77%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

BKD Brookdale Senior Living
$6.79 /

-0.155 (-2.23%)

BEAM Beam Therapeutics
$59.83 /

+4.67 (+8.47%)

AVTR Avantor
$34.90 /

+0.42 (+1.22%)

ALNY Alnylam
$158.89 /

+5.92 (+3.87%)

VOR Vor Bio
$7.85 /

+0.17 (+2.21%)

THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

PFE Pfizer
$52.93 /

+0.69 (+1.32%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

AZTA Azenta
$84.77 /

+7.52 (+9.73%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.